Cancer Family
Salivary Gland Neoplasm
CI-CAN-00000343Explore in graph →
Non-malignant74 active trials13 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000343Explore in graph →
Clinical trials
267 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06054178 | Identification of Nerves Using Fluorescein Sodium | completed | Phase 2 | 8 | Stanford UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05694819 | Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY) | completed | Phase 2 | 57 | National Cancer Center Hospital EastOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab |
| completed |
| Phase 2 |
| 55 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Mar 10, 2026 |
| clinicaltrials |
| NCT02047474 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 46 | Yale UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03172624 | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | completed | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06521775 | An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 6 | Mayo ClinicOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT02098538 | Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04420689 | Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery | completed | Phase 1 / Phase 2 | 27 | Alume Biosciences, Inc.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT01969578 | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | completed | Phase 2 | 149 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Nov 5, 2024 | clinicaltrials |
| NCT03990571 | Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT02776163 | Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas | completed | Phase 2 | 107 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03691207 | A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations(ACCURACY) | completed | Phase 2 | 87 | Ayala Pharmaceuticals, Inc,INDUSTRY | 6 | Jan 31, 2024 | clinicaltrials |
| NCT03749460 | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | completed | Phase 1 / Phase 2 | 20 | University of WashingtonOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT02178436 | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | Mohammed Najeeb Al HallakOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01703455 | Activity of Sorafenib in Salivary Gland Cancer | completed | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04291300 | Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients(LUPSA) | completed | Phase 2 | 12 | Radboud University Medical CenterOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT03999684 | A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03087019 | Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT03132038 | Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck(NISCAHN) | completed | Phase 2 | 98 | UNICANCEROTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03639168 | Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) | completed | Phase 2 | 22 | Fudan UniversityOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01666730 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT00031694 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2021 | clinicaltrials |
| NCT01175980 | Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 3, 2020 | clinicaltrials |
| NCT01044433 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02393820 | Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma(PACSA-ORL02) | completed | Phase 2 | 72 | UNICANCEROTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01065844 | Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck | completed | Phase 2 | 15 | University of IowaOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02857712 | Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14(SGC-AX14) | completed | Phase 2 | 26 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01604772 | Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | May 1, 2019 | clinicaltrials |
| NCT02123511 | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01524692 | Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma(ACC) | completed | Phase 2 | 35 | University of VirginiaOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01613768 | Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer | completed | Phase 2 | 29 | University of WashingtonOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT00859937 | Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 2 | Apr 20, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01316757 | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | completed | Phase 2 | 24 | Fox Chase Cancer CenterOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT01234935 | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | completed | Phase 2 | 8 | Translational Oncology Research InternationalOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01558661 | Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00509002 | Iressa Study in Patients With Salivary Gland Cancer | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01256385 | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy(MAESTRO HN) | completed | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Mar 27, 2017 | clinicaltrials |
| NCT00095628 | SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00581360 | Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck | completed | Phase 2 | 10 | University of PittsburghOTHER | 1 | Nov 7, 2016 | clinicaltrials |
| NCT01658943 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy(S1115) | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT01488838 | A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | completed | Phase 2 | 120 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01678105 | A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands(DOVE) | completed | Phase 2 | 21 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 17, 2015 | clinicaltrials |
Data updated 22 days agoSource updated May 20, 2026source: clinicaltrials